Table 1.
Studies included in the whole-brain meta-analyses identifying the neural correlates of progressive supranuclear palsy with structural magnetic resonance imaging.
| Study | PSP (N) | HC (N) | Age (years) | Gender (male/ female) | Disease Duration (years) | MMSE | UPDRS-III | Notes | Criteria |
|---|---|---|---|---|---|---|---|---|---|
| Gray matter studies | |||||||||
| Boxer et al., 2006 | 15 | 80 | 70.9 ± 6.9 | 9/6 | 4.8 ± 1.7 | 24.0 ± 3.2 | NR | a,b | Litvan |
| Brenneis et al., 2004 | 12 | 12 | 67.5 ± 6.6 | NR | 2.7 ± 0.9 | NR | 38.9 ± 10.9 | a,b | Litvan |
| Burciu et al., 2015 | 20 | 20 | 67.8 ± 7.1 | 10/10 | 2.6 ± NR | NR | 39.0 ± 14.5 | a,b,* | Litvan |
| Cordato et al., 2005 | 21 | 23 | 70.3 ± 6.4 | 14/7 | 4.0 ± 2.8 | 25.4 ± 3.2 | 23.1 ± 10.1 | a,b | Litvan |
| Ghosh et al., 2012 | 23 | 22 | 71.1 ± 8.6 | 14/9 | 2.5 | NR | 33.8 ± 15.7 | a,b,* | Litvan |
| Giordano et al., 2013 | 15 | 15 | 68.9 ± 1.2 | 8/7 | 3.2 ± 1.3 | 21.2 ± 1.2 | 38.3 ± 4.0 | a,b,* | Litvan |
| Kamiya et al., 2013 | 16 | 21 | 71.4 ± 6.0 | 10/6 | NR | NR | NR | b | Litvan |
| Lagarde, 2015 | 21 | 18 | 65.5 ± 6.5 | 8/13 | 4.4 ± 1.7 | 25.8 ± 2.7 | NR | a,b* | Litvan |
| Lehericy et al., 2010 | 10 | 9 | 66.9 ± 6.4 | 6/4 | 4.3 ± 1.0 | 27.0 | 30.0 | a,b | Litvan |
| Padovani et al., 2006 | 14 | 14 | 73.0 ± 5.6 | 7/7 | 3.1 ± 1.0 | 25.8 ± 2.7 | 22.1 ± 8.9 | a,b | Litvan |
| Piattella et al., 2015 | 16 | 16 | 68.1 ± 5.9 | 9/7 | 3.1 ± NR | 24.3 ± 3.9 | 27.0 ± 3.9 | a,b,* | Litvan |
| Premi et al., 2016 | 32 | 32 | 73.5 ± 6.9 | 17/15 | 6.9 ± 3.5 | 24.9 ± 3.9 | NR | b | Litvan |
| Sandhya et al., 2014 | 10 | 8 | NR | 9/1 | NR | NR | NR | a,b,* | Litvan |
| Takahashi et al., 2011 | 16 | 20 | 64.6 ± 6.4 | 11/5 | NR | 21.0 ± 4.4 | NR | b | Litvan |
| Whitwell et al., 2013 | 16 | 20 | 72.1 ± 4.6 | 8/8 | 4.1 ± NR | 25.8 ± 2.7 | 52.9 ± 12.6 | b,* | Litvan |
| Total GM | ∑257 | ∑334 | 69.4 ± 2.8 | 140/105 | 3.9 ± 1.2 | 24.5 ± 2.0 | 33.9 ± 9.7 | ||
| White matter studies | |||||||||
| Boxer et al., 2006 | 15 | 80 | 70.9 ± 6.9 | 9/6 | 4.8 ± 1.7 | 24.0 ± 3.2 | NR | a,b | Litvan |
| Brenneis et al., 2004 | 12 | 12 | 67.5 ± 6.6 | NR | 2.7 ± 0.9 | NR | 38.9 ± 10.9 | a,b | Litvan |
| Burciu et al., 2015 | 20 | 20 | 67.8 ± 7.1 | 10/10 | 2.6 ± NR | NR | 39.0 ± 14.5 | a,b,* | Litvan |
| Cordato et al., 2005 | 21 | 23 | 70.3 ± 6.4 | 14/7 | 4.0 ± 2.8 | 25.4 ± 3.2 | 23.1 ± 10.1 | a,b | Litvan |
| Ghosh et al., 2012 | 23 | 22 | 71.1 ± 8.6 | 14/9 | 2.5 | NR | 38.3 ± 4.0 | a,b,* | Litvan |
| Hughes et al., 2014 | 13 | 15 | 68.0 ± 6.8 | 9/4 | 4.3 ± 3.1 | 26.9 ± 2.9 | 29.2 ± 14.3 | b,* | Litvan |
| Lagarde, 2013 | 19 | 18 | 65.9 ± 6.5 | 7/12 | 4.5 ± 1.8 | 25.5 ± 2.7 | NR | a,b,* | Litvan |
| Lehericy et al., 2010 | 10 | 9 | 66.9 ± 6.4 | 6/4 | 4.3 ± 1.0 | 27.0 | 30,0 | a,b | Litvan |
| Price, 2004 | 12 | 12 | 65.3 ± 5.8 | 7/5 | 4.8 ± 1.7 | 27.0 ± 3.3 | 20.4 ± 8.7 | a,b | Litvan |
| Sakurai et al., 2015 | 33 | 32 | 78.0 ± 6.0 | 20/13 | 4.8 ± 2.6 | NR | NR | Litvan | |
| Takahashi et al., 2011 | 16 | 20 | 64.6 ± 6.4 | 11/5 | NR | 21.0 ± 4.4 | NR | b | Litvan |
| Whitwell et al., 2017 | 16 | 20 | 72.1 ± 4.6 | 8/8 | 4.1 ± NR | 25.8 ± 2.7 | 52.9 ± 12.6 | b,* | Litvan |
| Total WM | ∑210 | ∑265 | 69.0 ± 3.7 | 115/99 | 4.1 ± 0.8 | 25.3 ± 2.0 | 34.0 ± 10.5 | ||
| Total GM + WM | ∑315 | ∑393 | 69.2 ± 3.2 | 176/127 | 4.0 ± 1.0 | 24.9 ± 2.0 | 33.9 ± 9.7 | ||
Gender, age, disease duration, MMSE and UPDRS scores are specified for patients (mean ± standard deviation). All MRI studies used 1.5 T (except for * = 3 T). Disease duration mean scores were calculated without Gosh et al. because they reported data as median. Abbreviations: GM gray matter, HC healthy controls, MMSE mini-mental state examination, N number of subjects, NR not reported, PSP progressive supranuclear palsy, UDPRS-III motor score of unified Parkinson's disease rating scale, WM white matter. a corrected for multiple comparisons, b modulated